Literature DB >> 17289033

p14ARF interacts with N-Myc and inhibits its transcriptional activity.

Stefano Amente1, Barbara Gargano, Daniel Diolaiti, Giuliano Della Valle, Luigi Lania, Barbara Majello.   

Abstract

In this study, we report that the human p14(ARF) associates in vivo with the N-Myc and inhibits N-Myc mediated transcriptional activation. We have determined that the region (aa 140-300) encompassing the N-Myc BoxIII is required for efficient interaction in vivo. Furthermore, we demonstrate that in the SK-N-BE neuroblastoma cell line p14(ARF) over-expression delocalized N-Myc from the nucleoplasm into nucleoli and that N-Myc regions required for interaction with p14(ARF) are also important for nucleoli co-localization. Finally, we determine that the N-terminal region of the p14(ARF) protein is involved in binding to c-Myc and N-Myc proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289033     DOI: 10.1016/j.febslet.2007.01.062

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo.

Authors:  Sivashankar G Sivakolundu; Amanda Nourse; Simon Moshiach; Brian Bothner; Chimere Ashley; John Satumba; Jill Lahti; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2008-09-16       Impact factor: 5.469

2.  RasV12-mediated down-regulation of CCAAT/enhancer binding protein beta in immortalized fibroblasts requires loss of p19Arf and facilitates bypass of oncogene-induced senescence.

Authors:  Thomas Sebastian; Peter F Johnson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

3.  Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Authors:  Zaowen Chen; Yunfu Lin; Eveline Barbieri; Sue Burlingame; John Hicks; Andrew Ludwig; Jason M Shohet
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

4.  Myc proteins as therapeutic targets.

Authors:  W C Gustafson; W A Weiss
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

5.  MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Authors:  L D Gamble; U R Kees; D A Tweddle; J Lunec
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

6.  Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma.

Authors:  Stefano Amente; Giorgio Milazzo; Maria Cristina Sorrentino; Susanna Ambrosio; Giacomo Di Palo; Luigi Lania; Giovanni Perini; Barbara Majello
Journal:  Oncotarget       Date:  2015-06-10

Review 7.  Dynamics of ARF regulation that control senescence and cancer.

Authors:  Aram Ko; Su Yeon Han; Jaewhan Song
Journal:  BMB Rep       Date:  2016-11       Impact factor: 4.778

Review 8.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.